Niagen Bioscience, Inc.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
NAGE$2.15-5.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at and
Consolidated Balance Sheets
(In thousands, except par values)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents, including restricted cash of $152 for both periods presented | $64,788 | $44,660 |
| Trade receivables, net of allowances of $147 and $95, respectively | 9,741 | 7,768 |
| Inventories | 20,424 | 9,192 |
| Assets held for sale | 541 | — |
| Prepaid expenses and other assets | 1,312 | 2,482 |
| Total current assets | 96,806 | 64,102 |
| Leasehold improvements and equipment, net | 1,323 | 1,719 |
| Intangible assets, net | 5,660 | 359 |
| Right-of-use assets | 2,192 | 1,730 |
| Other long-term assets | 425 | 368 |
| Total assets | $106,406 | $68,278 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities | ||
| Accounts payable | $10,796 | $8,526 |
| Accrued expenses | 7,722 | 7,817 |
| Current maturities of operating lease obligations | 1,002 | 982 |
| Current maturities of finance lease obligations | — | 12 |
| Customer deposits | 399 | 611 |
| Total current liabilities | 19,919 | 17,948 |
| Deferred revenue | 2,674 | 2,579 |
| Operating lease obligations, less current maturities | 1,815 | 1,657 |
| Deferred consideration liability | 5,465 | — |
| Total liabilities | 29,873 | 22,184 |
| Commitments and Contingencies (Notes 9 and 15) | ||
| Stockholders' Equity | ||
| Common stock, $0.001 par value; authorized 150,000 shares; 79,714 shares and 77,330 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively. | 79 | 77 |
| Additional paid-in capital | 240,991 | 227,931 |
| Accumulated deficit | (164,528) | (181,910) |
| Cumulative translation adjustments | (9) | (4) |
| Total stockholders' equity | 76,533 | 46,094 |
| Total liabilities and stockholders' equity | $106,406 | $68,278 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.